Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Benitec Biopharma Limited (BNTC : NSDQ)

• Company Description    Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $11.23 Daily Weekly Monthly 20 Day Moving Average: 95,566 shares Shares Outstanding: 34.35 (millions) Market Capitalization: $385.80 (millions) Beta: 0.28 52 Week High: $17.15 52 Week Low: $9.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.57% -15.89% 12 Week 0.36% -7.22% Year To Date -16.63% -22.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3940 Trust Way - Hayward,CA 94545 USA ph: 510-780-0819 fax: 61 (0)3 9966-9923 brian.korb@astrpartners.com http://www.benitec.com

• General Corporate Information    Officers Jerel Banks - Chief Executive Officer; Chairman of the Board and Megan Boston - Chief Financial Officer; Director J. Kevin Buchi - Director Peter Francis - Director Edward Smith - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 08205P209 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 09/28/26 Share - Related Items Shares Outstanding: 34.35 Most Recent Split Date: 7.00 (0.06:1) Beta: 0.28 Market Capitalization: $385.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/28/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.10 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 7.69% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -34.82 12/31/25 - -38.92 09/30/25 - -46.75 ROA 03/31/26 - -34.11 12/31/25 - -37.68 09/30/25 - -44.84 Current Ratio 03/31/26 - 56.82 12/31/25 - 67.69 09/30/25 - 46.95 Quick Ratio 03/31/26 - 56.82 12/31/25 - 67.69 09/30/25 - 46.95 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 5.34 12/31/25 - 5.47 09/30/25 - 3.57 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.21 12/31/25 - 0.28 09/30/25 - 0.43

Powered by Zacks Investment Research ©